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INTRODUCTION
Hypersensitivity syndrome is an idiosyncratic, serious drug
reaction that consists of a rash, fever, involvement of multi-
ple visceral organs, and hematological abnormalities such as
eosinophilia. To better individualize drug hypersensitivity
reaction and to distinguish the hypersensitivity reaction from
drug-induced pseudolymphoma, Bocquet et al. have recently
introduced the term drug rash with eosinophilia and systemic
symptoms (DRESS) syndrome (1). Anticonvulsants are the
principal drugs responsible for this malady. Among them,
arene oxide producing aromatic anticonvulsants such as pheny-
toin and carbamazepine are the particular drugs most fre-
quently implicated for DRESS syndrome or the anticonvul-
sant hypersensitivity syndrome (AHS) (2-10).
Cross-reactivity among the aromatic anticonvulsants fre-
quently occurs when a previous history of DRESS syndrome
exists (10-12). Many studies have described cross sensitivity
as a worsening of the initial features of DRESS syndrome when
switching from a sensitive anticonvulsant to a cross-reactive
anticonvulsant (8, 13-15). However limited data have describ-
ed the development of DRESS syndrome after switching me-
dication from a previously well-tolerated anticonvulsant to
another (5-7). 
We present here a case of DRESS syndrome in which hyper-
sensitivity reaction to a previously well-tolerated phenytoin
was induced by hypersensitivity to carbamazepine, and we
show that the patch test may be a useful method for detect-
ing possible cross-reactive drugs in such situations. 
CASE REPORT
A 40-yr-old man suffering from epilepsia presented with
a generalized skin rash, facial edema, sore throat and high-
grade fever of 3-day duration. He had been taken phenytoin
and sodium valproate for 4 yr without having any adverse
reaction. Because of several attacks of seizure while taking
these anticonvulsants, the medications were switched to car-
bamazepine and sodium valproate 16 weeks before the onset
of skin rash and fever. 
At admission his temperature was 38.9℃, blood pressure
90/50 mmHg, pulse 140 beats/min, and respiratory rate 17
breaths/min. On physical examination, generalized, diffuse,
maculopapular, erythematous, pruritic rash was noted over
the face, trunk and extremities with marked facial edema
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Drug Hypersensitivity to Previously Tolerated Phenytoin by 
Carbamazepine-induced DRESS Syndrome
Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome associat-
ed with anticonvulsant drugs is a rare but potentially life-threatening disease that
occurs in response to arene oxide producing anticonvulsant such as phenytoin and
carbamazepine. There have been many reports of cross reactivity among the anti-
convulsants upon first exposure to the offending drugs. However, there has been
few data describing the development of DRESS syndrome after switching medica-
tion from previously well-tolerated phenytoin to carbamazepine, and the induction
of hypersensitivity to phenytoin by DRESS to carbamazepine. We experienced a
case of a 40-yr-old man who had uncontrolled seizure that led to the change of medi-
cation from the long-term used phenytoin to carbamazepine. He developed DRESS
syndrome after changing the drugs. We stopped carbamazepine and restored phe-
nytoin for seizure control, but his clinical manifestations progressively worsened and
he recovered only when both drugs were discontinued. Patch tests with several anti-
convulsants showed positive reactions to both carbamazepine and phenytoin. Our
case suggests that hypersensitivity to a previously tolerated anticonvulsant can be
induced by DRESS to another anticonvulsant, and that the patch test may be a use-
ful method for detecting cross-reactive drugs in anticonvulsant-associated DRESS
syndrome.
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(Fig. 1). He had moderately enlarged tonsils, injected oro-
pharynx, and bilateral cervical lymphadenopathy. His neu-
rological examination and the remainder of the physical ex-
amination were unremarkable. 
The laboratory studies showed a leukocytosis of 16.1×109/
L with an eosinophilia of 2.7×109/L (Table 1). The platelet
count and coagulation profile were normal. The c-reactive
protein was high at 11.3 mg/dL (normal <0.3 mg/dL), and
the erythrocyte sedimentation rate was 2 mm in the first hour.
Liver function tests revealed aspartate aminotransferase 68
IU/L (normal 10-59 IU/L), alanine aminotransferase 122 IU/
L (normal 10-72 IU/L), alkaline phosphatase 232 IU/L (nor-
mal 30-140 IU/L), and serum bilirubin 0.4 mg/dL. Serology
for antinuclear factor, RA factor, HBS Ag, anti-HIV antibo-
dies, anti-Mycoplasma antibodies, IgM anti-EB virus anti-
bodies, anti-Hantan virus antibodies, anti-leptospiral anti-
bodies, anti-rickettsial antibodies, p-ANCA and c-ANCA
antibodies was all negative. The other laboratory tests were
all negative. Skin biopsy showed moderate perivascular and
interstitial infiltration of lymphocytes, eosinophils with exo-
cytosis, basal cell vacuolization and marked upper dermal
edema.
The diagnosis of DRESS syndrome due to carbamazepine
was proposed on the basis of his clinical and biological find-
ings. Carbamazepine was discontinued, phenytoin was restart-
Fig. 1. Generalized di-
ffuse maculopapular
rashes over the face
and trunk with facial
edema on the day of
admission.
Days after admission
2 4 7 9 14 21 60
On 
admission
Highest temperature ( ° C) 38.9 39.6 40.0 38.7 37.1 37.0 36.7 36.7
White blood cell (×10
3/ L) 16.1 30.2 55.9 80.3 45.2 12.9 13.1 8.9
Neutrophils (%) 54.6 39.0 30.1 25.0 29.0 58.0 54.2 40.2
Eosinophils (%) 17.0 24.0 28.0 32.0 18.0 8.0 2.2 4.0
Serum albumin (g/dL) 2.5 2.0 2.9 3.0 3.6 4.0
Aspartate aminotrasferase (IU/L) 68 39 23 35 19 31
Alanine aminotrasferase (IU/L) 122 64 33 66 43 25
Medication
Prednisolone (mg/day) 40 40 40 40 60 30 20 0
Phenytoin (mg/day) 300 300 300 0
Topiramate (mg/day) 100 100 100 100 250
Sodium valproate (mg/day) 1,200 1,200 1,200 1,200 1,200 1,200 1,200 1,200
Table 1. Laboratory values and clinical characteristics
Fig. 2. Desquamative facial rash and edema (A), and vesiculation on upper arms (B). Photographs taken at seventh admission day with
prednisolone (40 mg/day) treatment.
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ed at the dose of 300 mg/day, and he was also treated with
prednisolone (40 mg/day). However, during the next 7 days
his skin rashes and facial edema progressively worsened, and
mucosal lesions developed with the persistence of fever (Fig.
2). Rapid progression of the leukocytosis with an eosinophilia
was also noted (Table 1). On the seventh day of hospitaliza-
tion, phenytoin was stopped while continuing prednisolone
based on a presumed diagnosis of hypersensitivity reaction
to phenytoin. Topiramate (100 mg/day) was then added for
seizure control. There was marked improvement in his gen-
eral condition over the next several days with subsidence of
the fever. Following the resolution of his skin eruption and
laboratory abnormalities, the prednisolone was tapered over
the next 3 weeks.
After obtaining informed consent, patch test was performed
3 months after the total resolution of his illness. Several anti-
convulsants including carbamazepine and phenytoin were
tested at concentrations of 1% and 10% in petrolatum with/
without 1% and 10% in water. Using Finn Chambers on
Scanopor tape, 2-day closed patch testing was performed on
the backs of the patient. The reactions were scored at 30 min
after removal and 4 days after application, according to the
International Contact Dermatitis Research group recommen-
dations (16, 17). Carbamazepine and phenytoin patch tests
were positive at day 2 and day 4, however, phenobarbital, sodi-
um valproate, topiramate, gabapentin, and vigabatrin showed
no significant response on the patch tests (Fig. 3, Table 2).
At a follow-up examination after 12 months, he was com-
pletely asymptomatic and was tolerating sodium valproate
(1,200 mg/day) and topiramate (250 mg/day).
DISCUSSION
DRESS syndrome can manifest 1-8 weeks after starting
the anticonvulsant therapy with a mean of 3 weeks (11-13,
18). In previously sensitized individuals, DRESS may occur
within 1 day upon rechallenge. In our case, DRESS syndrome
developed 16 weeks after the introduction of carbamazepine.
The patient had no known exposure to other medications that
have been implicated in development of the DRESS syndro-
me. Various factors may have contributed to this long induc-
tion period; interindividual variations, individual suscepti-
bility, and induction of the carbamazepine metabolism via
the hepatic cytochrome P-450 system by the previously ad-
ministered phenytoin, which might have reduced the ten-
dency to develop DRESS syndrome.
Cross sensitivity among the aromatic anticonvulsants occurs
at a rate as high as 80% (11, 12). However, development of
DRESS syndrome to one anticonvulsant after switching med-
ication, and the subsequent development of hypersensitivity
to a previously well-tolerated anticonvulsant upon second
exposure rarely occurs (5-7). For most of these cases, there
was no objective evidence about secondary induction of hy-
persensitivity to a previously tolerated drug, and only a pre-
sumptive diagnosis was made based on the clinical manifes-
tations (5, 7). Some patients with DRESS syndrome may have
flare-up of symptoms 3 to 4 weeks after the initiation of the
reaction despite the discontinuation of the offending drug.
In addition, once the offending drug is discontinued, those
organs initially involved may show progressive changes or
organs that were previously uninvolved may manifest involve-
ment (11). Therefore, we cannot exclude the possibility that
the worsening of the clinical features was not due to cross-reac-
tivity but due to the natural course of the DRESS syndrome
in some reports (5, 7). Klassen and Sadler (6) only showed
induction of hypersensitivity to the previously tolerated phe-
nytoin by carbamazepine with the reintroduction of pheny-
Fig. 3. Results of drug patch testing at day 2. 1, petrolatum; 2, phe-
nytoin 10% aq; 3, phenytoin 1% aq; 4, phenobarbital 10% pet; 5,
phenobarbital 1% pet; 6, phenytoin 10% pet; 7, phenytoin 1% pet;
8, carbamazepine 10% aq; 9, carbamazepine 1% aq; 10, carba-
mazepine 10% pet; 11, carbamazepine 1% pet; 12, carbamaze-
pine 0.5% pet; 13, carbamazepine 0.1% pet; 14, sodium valproate
10% pet; 15, sodium valproate 1% pet; 16, topiramate 10% pet;
17, topiramate 1% pet; 18, gabapentin 10% pet; 19, gabapentin
1% pet; 20, vigabatrin 10% pet. aq, in water; pet, in petrolatum.
Readings
Day 2 Day 4
Anticonvulsants
Carbamazepine 10% pet. ++ ++
Carbamazepine 1% pet. + +
Carbamazepine 10% aq. + +
Carbamazepine 1% aq. +/- +
Phenytoin 10% pet. + +
Phenytoin 1% pet. + +
Phenytoin 10% aq. +/- +
Phenytoin 1% aq. --
Phenobarbital 10% and 1% pet. --
Sodium valproate 10% and 1% pet. --
Topiramate 10% and 1% pet. --
Gabapentin 10% and 1% pet. --
Table 2. Summary of patch test results with several anticonvul-
sants







20DRESS Syndrome to Carbamazepine and Phenytoin 771
toin to the patient. The initial lack of adverse reaction to phe-
nytoin, followed by immediate adverse response on later re-
challenge several months after development of hypersensitivity
to carbamazepine indirectly suggest induction of hypersen-
sitivity to phenytoin in that report. Besides the clinical fea-
tures, we showed induction of hypersensitivity to phenytoin
with the results of the patch tests.
The diagnosis of DRESS syndrome is made based on the
history of drug exposure and clinical examination. The dif-
ferential diagnosis includes other cutaneous drug reactions,
acute infections, neoplastic, and other immunologic disorders.
Withdrawal of the suspicious drug and subsequent improve-
ment of clinical manifestations makes the diagnosis more
reliable. When anticonvulsant therapy is invaluable, however,
additional diagnostic methods can be sought to select safe
drugs for seizure control. Although no gold standard exists,
in vitro lymphocyte toxicity assay or lymphocyte transforma-
tion tests (LTT), and in vivo patch tests may be helpful in such
situations. Many studies have showed the usefulness of LTT
and patch testing for the diagnosis of hypersensitivity to anti-
convulsants (11, 12, 17-23). LTT shows similar results with
patch test. But false negative reaction of LTT was also noted
in patients with simultaneous positive patch test (20). As patch
testing is less cumbersome and seems more reliable, it is more
frequently used in the case of diagnostic uncertainty (17, 19-
24). Positive rate of patch tests to carbamazepine were rela-
tively high from 70% to 100% (20-24). However, positive
patch test results in phenytoin-induced AHS were much lower
(30-60%) than in carbamazepine-induced AHS (25, 26).
Moreover, it is not yet known accurately how many patients
who are on anticonvulsants have a positive patch test. Thus
the diagnostic accuracy of patch test in DRESS syndrome is
currently unknown. In general, positive predictive value of
patch test is relatively good, but negative results of patch test
cannot exclude the possibility of hypersensitivity. If patch
testing is to be performed, 1% and 10% carbamazepine or
phenytoin in petrolatum, in water or in alcohol is recommend-
ed (11, 19). It is also recommended that at least 2 months
should elapse from the time of the skin eruption to the test-
ing date since either false positive reactions due to increased
reactivity or false negative reactions due to a refractory state
may exist. We performed patch tests 3 months after the total
resolution of symptoms with several anticonvulsants at 1%
and 10% concentrations, and both carbamazepine and pheny-
toin showed positive results. Although we did not perform
an oral rechallenge testing with phenytoin, the imputability
of these two drugs was possible because of the clinical features
and the in vivo patch test results.
Aromatic anticonvulsants are metabolized by the cyto-
chrome P-450 enzyme to a common arene oxide metabolite
that is normally detoxified by enzyme systems such as epox-
ide hydrolase. Genetically determined abnormalities in en-
zyme systems leading to inability to detoxify toxic metabo-
lites may be involved in the pathogenesis of AHS (11, 12,
25). Reactive toxic metabolites irreversibly modify cellular
proteins, and then initiate or serve as targets for an immune
attack on modified proteins in target organs (27, 28). Thus
both pharmacogenetic and immunologic mechanism may
play an important role in anticonvulsant-induced DRESS
syndrome, and this immune response can explain the late
induction of hypersensitivity to the previously tolerated phe-
nytoin after sensitization to carbamazepine. Recent studies
have strongly suggested that viral infections, especially reac-
tivation of human herpesvirus 6, contribute to the pathogen-
esis of drug hypersensitivity to anticonvulsants (4, 9, 10).
However further study will be required to establish the rela-
tionship between human herpesvirus 6 infection and drug
hypersensitivity.
In conclusion, we present a case of carbamazepine-induced
DRESS syndrome that also showed induction of hypersensi-
tivity to the previously well-tolerated phenytoin. Our case
suggests that physician should be aware that hypersensitivity
to previously tolerated anticonvulsants can be induced by hy-
persensitivity to another anticonvulsant, and patch test may be
a worthwhile method for detecting other possible cross-reac-
tive drugs in such situations. 
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